Rabjerg Maj, Oliván-Viguera Aida, Hansen Lars Koch, Jensen Line, Sevelsted-Møller Linda, Walter Steen, Jensen Boye L, Marcussen Niels, Köhler Ralf
Department of Pathology, Odense University Hospital, DK-5000 Odense C, Denmark.
Aragon Institute of Health Sciences I+CS/IIS, 50009 Zaragoza, Spain.
PLoS One. 2015 Apr 7;10(4):e0122992. doi: 10.1371/journal.pone.0122992. eCollection 2015.
Ca2+-activated K+ channels have been implicated in cancer cell growth, metastasis, and tumor angiogenesis. Here we hypothesized that high mRNA and protein expression of the intermediate-conductance Ca2+-activated K+ channel, KCa3.1, is a molecular marker of clear cell Renal Cell Carcinoma (ccRCC) and metastatic potential and survival.
METHODOLOGY/PRINCIPAL FINDINGS: We analyzed channel expression by qRT-PCR, immunohistochemistry, and patch-clamp in ccRCC and benign oncocytoma specimens, in primary ccRCC and oncocytoma cell lines, as well as in two ccRCC cell lines (Caki-1 and Caki-2). CcRCC specimens contained 12-fold higher mRNA levels of KCa3.1 than oncocytoma specimens. The large-conductance channel, KCa1.1, was 3-fold more highly expressed in ccRCC than in oncocytoma. KCa3.1 mRNA expression in ccRCC was 2-fold higher than in the healthy cortex of the same kidney. Disease specific survival trended towards reduction in the subgroup of high-KCa3.1-expressing tumors (p<0.08 vs. low-KCa3.1-expressing tumors). Progression-free survival (time to metastasis/recurrence) was reduced significantly in the subgroup of high-KCa3.1-expressing tumors (p<0.02, vs. low-KCa3.1-expressing tumors). Immunohistochemistry revealed high protein expression of KCa3.1 in tumor vessels of ccRCC and oncocytoma and in a subset of ccRCC cells. Oncocytoma cells were devoid of KCa3.1 protein. In a primary ccRCC cell line and Caki-1/2-ccRCC cells, we found KCa3.1-protein as well as TRAM-34-sensitive KCa3.1-currents in a subset of cells. Furthermore, Caki-1/2-ccRCC cells displayed functional Paxilline-sensitive KCa1.1 currents. Neither KCa3.1 nor KCa1.1 were found in a primary oncocytoma cell line. Yet KCa-blockers, like TRAM-34 (KCa3.1) and Paxilline (KCa1.1), had no appreciable effects on Caki-1 proliferation in-vitro.
CONCLUSIONS/SIGNIFICANCE: Our study demonstrated expression of KCa3.1 in ccRCC but not in benign oncocytoma. Moreover, high KCa3.1-mRNA expression levels were indicative of low disease specific survival of ccRCC patients, short progression-free survival, and a high metastatic potential. Therefore, KCa3.1 is of prognostic value in ccRCC.
钙激活钾通道与癌细胞生长、转移及肿瘤血管生成有关。在此,我们推测中间电导钙激活钾通道KCa3.1的高mRNA和蛋白表达是透明细胞肾细胞癌(ccRCC)、转移潜能及生存的分子标志物。
方法/主要发现:我们通过qRT-PCR、免疫组织化学及膜片钳技术分析了ccRCC和良性嗜酸性细胞瘤标本、原发性ccRCC和嗜酸性细胞瘤细胞系以及两种ccRCC细胞系(Caki-1和Caki-2)中的通道表达。ccRCC标本中KCa3.1的mRNA水平比嗜酸性细胞瘤标本高12倍。大电导通道KCa1.1在ccRCC中的表达比嗜酸性细胞瘤高3倍。ccRCC中KCa3.1的mRNA表达比同一肾脏的健康皮质高2倍。在高表达KCa3.1的肿瘤亚组中,疾病特异性生存呈下降趋势(与低表达KCa3.1的肿瘤相比,p<0.08)。在高表达KCa3.1的肿瘤亚组中,无进展生存期(转移/复发时间)显著缩短(与低表达KCa3.1的肿瘤相比,p<0.02)。免疫组织化学显示KCa3.1在ccRCC和嗜酸性细胞瘤的肿瘤血管以及部分ccRCC细胞中有高蛋白表达。嗜酸性细胞瘤细胞缺乏KCa3.1蛋白。在原发性ccRCC细胞系和Caki-1/2-ccRCC细胞中,我们在部分细胞中发现了KCa3.1蛋白以及对TRAM-34敏感的KCa3.1电流。此外,Caki-1/2-ccRCC细胞显示出对Paxilline敏感的KCa1.1电流。在原发性嗜酸性细胞瘤细胞系中未发现KCa3.1和KCa1.1。然而,KCa阻滞剂,如TRAM-34(KCa3.1)和Paxilline(KCa1.1),对Caki-1的体外增殖没有明显影响。
结论/意义:我们的研究表明KCa3.1在ccRCC中表达,但在良性嗜酸性细胞瘤中不表达。此外,高KCa3.1-mRNA表达水平表明ccRCC患者的疾病特异性生存期短、无进展生存期短且转移潜能高。因此,KCa3.1在ccRCC中具有预后价值。